MedTrace Logo

Aging Mammary Stem Cells and Breast Cancer Prevention

NCT02642094 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-12-05

Study results available
· View outcomes & findings →

Summary

To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens

Conditions

  • Cancer of Breast

Interventions

DRUG

Rapamycin

Low dose of rapamycin at 2 mg/day for -5-7 days of treatment

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • LuZhe Sun

    lead OTHER

Principal Investigators

  • LuZhe Sun, PhD · University of Texas Health Science Center San Antonio, Co-PI

  • Ismail Jatoi, MD · University of Texas Health Science Center San Antonio

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2022-03-01
Completion
2022-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02642094 on ClinicalTrials.gov